ETIDIOH - NEW

{Northern Ireland} 56 week-old hens-table egg layers. Positive test for HPAI H5N1, clinical signs presented prior to testing. 10-week-old approx. turkey broilers. Positive test for HPAI H5N1, clinical signs presented prior to testing. Source: WOAH,  https://wahis.woah.org/#/in-review/7000 ____

  A poultry farm in Sachsen Region. Source: WOAH,  https://wahis.woah.org/#/in-review/7002 ____

Wild Mute Swans in Kiev Region. Source: WOAH,  https://wahis.woah.org/#/in-review/6994 ____

  Abstract In developing countries particularly in field conditions unfavorable environmental conditions, lack of availability of appropriate transport media (TM) and maintenance of cold chain during transport; sample collection , storage, and transportation is more challenging . Considering these facts, five TM out of which three laboratory-based media named phosphate-buffered saline (PBS), 50% glycerol + PBS , and normal saline (NS) and two commercially available media including viral transport medium (VTM), charcoal based viral transport medium (CVTM) were compared to protect infectivity of the H5N1 influenza virus . Spiked fecal sample and allantoic fluid with and without these TM were placed in field simulatory storage and transportation conditions and in every 12 h time interval these samples were tested for virus isolation in embryonated chicken egg inoculation and identification by HA test and RT PCR upto 7 days. Survivability of the virus was detected by calculating the pe...

  Abstract Background :  Lassa fever (LF) is an acute viral hemorrhagic illness endemic to West Africa, with no licensed vaccines or targeted treatments available, highlighting a critical gap in global health preparedness. T cell-mediated immunity plays a central role in viral control and survival. Synthetic DNA vaccines offer a promising strategy to induce both humoral and cellular immunity against LF. Methods :  A Phase 1b, randomized, double-blind, placebo-controlled trial was conducted to assess the safety, tolerability, and immunogenicity of INO-4500 , a DNA vaccine encoding the Lassa virus (Josiah strain) glycoprotein precursor (GPC). A total of 220 healthy adults were randomized to receive either 1 mg or 2 mg of INO-4500 (intervention), or placebo, administered intradermally (ID) followed by electroporation (EP) at Day 0 and Week 4. Safety was evaluated through Week 48. Primary immunogenicity endpoints included humoral and cellular immune responses at multiple time...